NIKKEI 225
27,466.61 +520.94 (+1.93%) HANG SENG
19,591.43 +332.67 (+1.73%) CRUDE OIL
70.03 -0.87 (-1.23%) GOLD FUTURES
1,970.60 +21.00 (+1.08%) DOW
32,030.11 -530.49 (-1.63%) Bitcoin GBP
22,299.96 -638.97 (-2.79%)
Quince Therapeutics, Inc. (QNCX)
After hours:
| Previous close | 1.4400 |
| Open | 1.4100 |
| Bid | 1.4200 x 1100 |
| Ask | 1.4200 x 1300 |
| Day's range | 1.3800 - 1.4800 |
| 52-week range | 0.5400 - 6.8000 |
| Volume | |
| Avg. volume | 2,311,462 |
| Market cap | 52.602M |
| Beta (5Y monthly) | 1.26 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.6700 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 3.00 |
- Business Wire
Quince Therapeutics Confirms Receipt of Unsolicited Acquisition Offer from Echo Lake Capital
SOUTH SAN FRANCISCO, Calif., March 22, 2023--Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today confirmed that it received an unsolicited offer to acquire the company from Echo Lake Capital. Quince’s Board of Directors, consistent with its fiduciary responsibilities, will carefully review and evaluate the proposal to determine the course of action it believes is in t
- Business Wire
Quince Therapeutics Provides Pipeline Update and Business Outlook for 2023
SOUTH SAN FRANCISCO, Calif., January 30, 2023--Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today provided an update on the company’s development pipeline and business outlook for 2023. The company intends to prioritize capital resources toward the expansion of its development pipeline through opportunistic in-licensing and acquisition of clinical-stage assets target
- Business Wire
Quince Therapeutics Completes the Sale of Legacy Protease Inhibitor Portfolio to Lighthouse Pharmaceuticals
SOUTH SAN FRANCISCO, Calif., January 27, 2023--Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, announced the sale of the company’s legacy small molecule protease inhibitor portfolio, including COR588, COR388, COR852, and COR803, pursuant to an asset purchase agreement with Lighthouse Pharmaceuticals, Inc., an entity co-founded by Casey Lynch, former chief executive officer of Quince’s pred
